The proximity of insider selling to a major corporate action (spin-off + private placement) raises concerns about insider sentiment ahead of structural changes. Traders should monitor for further selling, delays in the Form 10 filing for the spin-off, or downward revisions to guidance. Consider hedging ahead of spin-off execution.
Price Chart
Executive Summary
Two corporate insiders at AnaptysBio sold shares worth $731K within a 7-day window, including CEO Daniel Faga and Director John Schmid, shortly after the company announced a securities purchase agreement related to a spin-off of its subsidiary First Tracks Biotherapeutics. The timing suggests potential awareness of material non-public developments.
Key Financial Metrics
Key Facts
- CEO Daniel Faga and Director John Schmid sold a combined $731K in shares over 7 days
- Sales occurred between March 27 and March 30, 2026, immediately following an 8-K filing disclosing a material agreement for a spin-off and private placement
- Total insider selling represents approximately 0.046% of AnaptysBio's $1.6B market cap
- The 8-K (filed March 27) disclosed a securities purchase agreement for First Tracks Biotherapeutics, a wholly-owned subsidiary, to be spun off to AnaptysBio shareholders
Financial Impact
$731,000 in open-market sales by two insiders
Risk Factors
- Insider selling may signal lack of confidence in post-spin valuation or near-term prospects
- Private placement concurrent with spin-off could lead to dilution or perceived value transfer
- Regulatory or operational risks associated with the spin-off execution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ANAB-1775093331565 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | Institutional Cluster | $56.02 $53.87 | ▼ −3.84% | ▼ −2.09% | $48.53 (−13.37%) |
Jun 29, 2026 13w ago | 144 | $67.50 $53.61 | ▲ +20.58% | ▲ +19.55% | $48.53 (+28.10%) |
Jun 29, 2026 13w ago | DEFA14A | $67.50 $53.61 | ▼ −20.58% | ▼ −19.55% | $48.53 (−28.10%) |
Jun 26, 2026 13w ago | 144 | $65.97 $54.15 | ▲ +17.92% | ▲ +17.64% | $48.53 (+26.44%) |
Jun 22, 2026 14w ago | 8-K | $59.43 $50.29 | ▼ −15.38% | ▼ −16.54% | $48.53 (−18.34%) |
Jun 17, 2026 15w ago | 144 | $57.51 $54.15 | ▲ +5.84% | ▲ +6.38% | $48.53 (+15.61%) |
Jun 15, 2026 15w ago | 144 | $57.61 $62.51 | ▼ −8.51% | ▼ −8.31% | $48.53 (+15.76%) |
Jun 11, 2026 16w ago | 144 | $56.07 $66.39 | ▼ −18.41% | ▼ −16.63% | $48.53 (+13.45%) |
Jun 10, 2026 16w ago | 144 | $54.24 $66.59 | ▼ −22.77% | ▼ −20.88% | $48.53 (+10.53%) |
Jun 8, 2026 16w ago | 144 | $51.63 $67.33 | ▼ −30.40% | ▼ −28.95% | $48.53 (+6.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access